Michael Banton, MD
Child & Adolescent Psychiatry · Saint Louis, MONPI 1619984523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $895 and has fallen 73.9% since, to $234 in 2024.
Across 193 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$590
- Otsuka America Pharmaceutical, Inc.$428
- Corium, LLC$368
- Teva Pharmaceuticals USA, Inc.$365
- Neos Therapeutics, LP$219
- Takeda Pharmaceuticals U.S.A., Inc.$197
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$230
- CAPLYTA$126
- REXULTI$125
- UZEDY$122
- Austedo XR$105
How this compares
$3,327 in reported general payments places this provider in the 85th percentile of 90 child & adolescent psychiatry providers in Missouri.
See all child & adolescent psychiatry providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate ErMethylphenidate Hcl | 24 | $8,355 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $2,459 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,972 |
| Aripiprazole | 34 | $1,727 |
| Quetiapine Fumarate | 56 | $1,487 |
| Oxcarbazepine | 11 | $775 |
| Olanzapine | 11 | $656 |
| Fluoxetine Hcl | 73 | $622 |
| Buspirone Hcl | 15 | $554 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $513 |
| Sertraline Hcl | 18 | $501 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $450 |
| Benztropine Mesylate | 14 | $449 |
| Duloxetine Hcl | 14 | $444 |
| Bupropion XlBupropion Hcl | 11 | $353 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Saint Louis
- Ginger NicolSaint Louis$77K
- Jeffrey SchulmanSaint Louis$62K
- Joshua WilsonSaint Louis$22K
- Chad SylvesterSaint Louis$3K
- Paul GlaserSaint Louis$3K
- Oksana BaramSaint Louis$2K
- Afshan SultanaSaint Louis$1K
- Kelly BotteronSaint Louis$887
- Stephen IrwinSaint Louis$683
- Darin QuachSaint Louis$629
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.